Search for: "Laboratory Express, Inc."
Results 361 - 380
of 438
Sorted by Relevance
|
Sort by Date
24 Apr 2020, 6:58 am
Abbott Laboratories has drawn praise for developing a relatively reliable, fast diagnostic test for COVID-19, but (at least as of mid-April 2020) its manufacturing capacity has been unable to keep up with demand. [read post]
27 Sep 2007, 11:38 am
Wyeth-Ayerst Laboratories, 385 F.3d 961, 963-64 (6th Cir. 2004); Flynn v. [read post]
1 Jun 2010, 8:16 am
He was the lead trial lawyer for Forest Laboratories Inc. in an effort to block Teva Pharmaceutical Industries Ltd. from selling a generic version of the antidepressant Lexapro. [read post]
23 Jan 2013, 1:02 am
., Inc. v. [read post]
23 Jan 2013, 1:02 am
., Inc. v. [read post]
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
21 Feb 2019, 4:00 am
Nette,[70] in an effort to avoid the Latin expression, described the Smithers standard as “a contributing cause that is not trivial or insignificant. [read post]
27 Apr 2007, 12:04 pm
By Hal WegnerBefore an overflow hearing room on an internationally available web broadcast, Chairman Howard Berman of the House Judiciary Subcommittee relevant to patents hosted a most informative and candid hearing yesterday afternoon joined by roughly ten of his committee colleagues, including Rep. [read post]
14 May 2012, 9:30 pm
The leading case appears to be the Fourth Circuit's 1999 ruling in Food Lion Inc. v. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
7 Apr 2010, 3:44 pm
Click Here EPA Settles with Drug and Laboratory Disposal on Hazardous Waste Violations. [read post]
18 Dec 2008, 10:36 pm
Syntex Laboratories, 499 N.E.2d 952, 962 (Ill. [read post]
1 Feb 2008, 12:00 am
: (IPBiz),State of the Union address 28 Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O),Alnylam Pharmaceuticals secures UK patent covering molecules that affect RNA interference: (SmartBrief),Doha style compulsory licences for exports: The politics…: (Spicy IP),Pushing to compulsory licensing: Pharma companies heading closer to Doha: (Spicy IP),Financial Express on the battle between big pharma companies and the… [read post]
2 Oct 2015, 11:30 am
Inc., MDL No. 2329, 1:13-cv-297-WSD, 2015 U.S. [read post]
1 Sep 2011, 8:31 am
Chief Judge Rader wrote a separate opinion to express “additional views,” which was joined by Judge Newman. [read post]
1 Sep 2011, 8:31 am
Chief Judge Rader wrote a separate opinion to express “additional views,” which was joined by Judge Newman. [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade Representative over Special 301… [read post]
15 Sep 2015, 5:53 am
“Investigators of Anthem Inc. [read post]
16 May 2008, 8:03 am
– Discussion of T Berg’s paper ‘IP and the preferential option for the poor’: (ISinIP), Patent valuation: differing analytical methods: (Hal Wegner) Global - Copyright Copyright as an engine of free expression? [read post]
Review of the Effects of the Leahy-Smith America Invents Act on Third Party Participation Applicants
1 Feb 2012, 9:15 am
Lastly, while there was no express experimental use defense, patent owners would be reluctant to accuse laboratories for infringement if the use was de minimis and purely experimental; the legal expense would exceed the expected damages, as there would be no demonstrable sales. [read post]
